Search the Newsreel

Glimpse Group (GGRP) director awarded 174,368 stock options at $0.77

Glimpse Group, Inc. director Tamar Elkeles was granted 174,368 stock options with an exercise price of $0.77 per share, vesting monthly over one year from the July 10, 2026 grant date. This new grant expires on July 10, 2036. Elkeles also holds several other …

Glimpse Group, Inc. (GGRP) investor Bruce Grossman reports 9.99% beneficial stake

Bruce Grossman has reported an amended beneficial ownership of 9.99% in Glimpse Group, Inc. (GGRP) common stock through an SEC Schedule 13G/A filing. This stake, totaling 2,215,698 shares, includes holdings through Dillon Hill Capital LLC and Dillon Hill Investment Company II LLC, with sole …

IPSEN - Buy-back programme - Art 5 of MAR - Week 31 - 2026

Ipsen Pharma Aggregated presentation by day and by market Weekly report on share repurchases from 27th July to 31st July 2026 Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Total daily volume (in number of …

Glimpse Group, Inc. Revenue Breakdown – MUN:9DR

This article details the revenue breakdown for Glimpse Group, Inc. (MUN:9DR). The company generated €8.94 million last year, with its Software Services segment contributing the most at €8.49 million. The United States was the primary geographic source of this revenue, accounting for the entire …

Glimpse Group (GGRP) grants ex-director over 97,000 stock options

The Glimpse Group (GGRP) has reported that former director Alexander Ruckdaeschel received two stock option awards totaling 97,917 shares. One grant for 37,500 shares at an exercise price of $2.25 vested monthly throughout 2025, while another for 60,417 shares at $0.69 vested immediately on …

Ipsen SA (IPSEY) (H1 2026) Earnings Call Highlights: Record Sales and Margin Growth Amid ...

This article first appeared on GuruFocus. Release Date: July 30, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Total sales grew 23.5% at constant exchange rates, with a record core operating margin of …

Ipsen slips despite raising outlook on broad-based drug sales growth

Investing.com -- Shares in French drugmaker Ipsen SA slippedon Thursday even as the company's second-quarter product sales of €1,115 million beat company-compiled consensus of €1,048 million by 6%, or €67 million, helped by strong Somatuline sales amid limited generic competition. Second-quarter product sales grew …

Ipsen delivers excellent H1 2026 results and upgrades its full-year guidance

Ipsen Pharma H1 2026 results with sales growth of 23.5% at CER1, or 20.4% as reported, with the portfolio beyond Somatuline® achieving sales growth of 24.8%1 and core operating income of €845m, growing by 28.8% as reported, with a core operating margin of 38.6% …

Ipsen (ENXTPA:IPN) Stock Looks Stretched On Earnings But Reasonable On Cash Flow

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Ipsen stock has delivered an 85.4% return over the past 5 years, yet the valuation picture is split, with the Discounted Cash Flow (DCF) …

Stock option awards to Glimpse Group, Inc. (GGRP) former director

Glimpse Group, Inc. reported that former director Jeffrey D. Enslin, through Perimetre Capital, LLC, received two stock option awards. The first award on May 1, 2026, was for 54,375 options with a $0.6900 exercise price that vested immediately. The second award on January 1, …

IPSEN - Buy-back programme - Art 5 of MAR - Week 30 - 2026

Ipsen Pharma Aggregated presentation by day and by market Weekly report on share repurchases from 20th July to 24th July 2026 Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Total daily volume (in number of …

GGRP|Glimpse Group Ord Shs|Price:0.875|Chg%:-0.089

This article provides detailed real-time market data for Glimpse Group Ord Shs (GGRP), including current price, historical performance, key financial figures, and analyst ratings. It also offers technical indicators and a peer comparison, highlighting the company's market trends and investment potential.

Ipsen provides update on Phase III BOLD trial in biliary atresia

Ipsen Pharma PARIS, FRANCE, 24 JULY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Phase III BOLD trial evaluating Bylvay versus placebo for patients living with biliary atresia (BA) who have already undergone a Kasai hepatoportoenterostomy (HPE) did not meet the …

Ipsen - Corrective statement amending the monthly disclosure of the total number of shares and voting rights as of June 30, 2026

Ipsen Pharma CORRECTIVE STATEMENT Corrective statement amending the monthly disclosure of the total number of shares and voting rights as of June 30, 2026, published on July 9, 2026 Paris, July 22, 2026 This corrective statement is issued pursuant to Article L. 233-8 II …

The Glimpse Group (VRAR) Registration Filing Summary

The Glimpse Group (VRAR) operates as an immersive technology provider focusing on enterprise VR, AR, and spatial computing solutions, primarily in the U.S. The company has shifted its focus to spatial computing, cloud, and AI-driven solutions with its flagship product, Spatial Core. As of …

Ipsen completes acquisition of Memo Therapeutics AG, adding first-in-class asset to Ipsen's Rare Disease pipeline

Ipsen Pharma PARIS, FRANCE, 22 JULY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today it has completed the acquisition of Memo Therapeutics AG, a late-stage biotech company focused on potravitug, an anti-BK polyomavirus monoclonal antibody. About potravitug Potravitug is a first-in-class monoclonal antibody …

IPSEN - Buy-back programme - Art 5 of MAR - Week 29 - 2026

Ipsen Pharma Aggregated presentation by day and by market Weekly report on share repurchases from 13th July to 17th July 2026 Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Total daily volume (in number of …

Here's Why We're Watching Eclipse Metals' (ASX:EPM) Cash Burn Situation

Eclipse Metals (ASX: EPM) Sparks Fresh Interest as Greenland and Critical Minerals Stories Heat Up

We Think Eclipse Metals (ASX:EPM) Can Afford To Drive Business Growth

Eclipse Metals Ltd (ASX:EPM) - Shares, Dividends & News

Eclipse Metals Limited (EPM.AX) Stock Price, News, Quote & History